C9ORF72: What It Is, What It Does, and Why It Matters
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
When the non-coding repeat expansion in the C9ORF72 gene was discovered to be the most frequent cause of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) in 2011, this gene and its derived protein, C9ORF72, were completely unknown. The mutation appeared to produce both haploinsufficiency and gain-of-function effects in the form of aggregating expanded RNAs and dipeptide repeat proteins (DPRs). An unprecedented effort was then unleashed to decipher the pathogenic mechanisms and the functions of C9ORF72 in order to design therapies. A decade later, while the toxicity of accumulating gain-of-function products has been established and therapeutic strategies are being developed to target it, the contribution of the loss of function starts to appear more clearly. This article reviews the current knowledge about the C9ORF72 protein, how it is affected by the repeat expansion in models and patients, and what could be the contribution of its haploinsufficiency to the disease in light of the most recent findings. We suggest that these elements should be taken into consideration to refine future therapeutic strategies, compensating for the decrease of C9ORF72 or at least preventing a further reduction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis
Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., Bruce, J., Schuck, T., Grossman, M., Clark, C. M., et al. (2006) · Science · doi:10.1126/science.1134108 · Cited by 6,576
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221
Classification of primary progressive aphasia and its variants
Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S. F., Ogar, J. M., Rohrer, J. D., Black, S., Boeve, B. F., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31821103e6 · Cited by 5,141
DeJesus-Hernandez, M., Mackenzie, I. R., Boeve, B. F., Boxer, A. L., Baker, M., Rutherford, N. J., Nicholson, A. M., Finch, N. A., Flynn, H., Adamson, J., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.09.011 · Cited by 4,936 · cited 8×
“…three RNA variants results in the production of two different isoforms: the 222-amino acid (aa) isoform (C9-short of 24 kDa) encoded by V1, while the 481-aa isoform (C9-long of 54 kDa) is encoded by V2 and V3 (Figure 1A; DeJesus-Hernandez et al., 2011; Renton et al., 2011; Gijselinck et al., 2012).”
BackgroundResultInfluentialA Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD
Renton, A. E., Majounie, E., Waite, A., Simón-Sánchez, J., Rollinson, S., Gibbs, J. R., Schymick, J. C., Laaksovirta, H., van Swieten, J. C., Myllykangas, L., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.09.010 · Cited by 4,409 · cited 6×
“Alternative splicing of these three RNA variants results in the production of two different isoforms: the 222-amino acid (aa) isoform (C9-short of 24 kDa) encoded by V1, while the 481-aa isoform (C9-long of 54 kDa) is encoded by V2 and V3 (Figure 1A; DeJesus-Hernandez et al., 2011; Renton et al., 2011; Gijselinck et a…”
BackgroundInfluentialArai, T., Hasegawa, M., Akiyama, H., Ikeda, K., Nonaka, T., Mori, H., Mann, D., Tsuchiya, K., Yoshida, M., Hashizume, Y., et al. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.10.093 · Cited by 2,732
Converging Mechanisms in ALS and FTD: Disrupted RNA and Protein Homeostasis
Ling, S.-C., Polymenidou, M., & Cleveland, D. W. (2013) · Neuron · doi:10.1016/j.neuron.2013.07.033 · Cited by 1,811
Majounie, E., Renton, A. E., Mok, K., Dopper, E. G., Waite, A., Rollinson, S., Chiò, A., Restagno, G., Nicolaou, N., Simon-Sanchez, J., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70043-1 · Cited by 1,210
C9orf72 nucleotide repeat structures initiate molecular cascades of disease
Haeusler, A. R., Donnelly, C. J., Periz, G., Simko, E. A. J., Shaw, P. G., Kim, M.-S., Maragakis, N. J., Troncoso, J. C., Pandey, A., Sattler, R., et al. (2014) · Nature · doi:10.1038/nature13124 · Cited by 978
RNA Toxicity from the ALS/FTD C9ORF72 Expansion Is Mitigated by Antisense Intervention
Donnelly, C. J., Zhang, P.-W., Pham, J. T., Haeusler, A. R., Mistry, N. A., Vidensky, S., Daley, E. L., Poth, E. M., Hoover, B., Fines, D. M., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.10.015 · Cited by 877
Differential regulation of mTORC1 by leucine and glutamine
Jewell, J. L., Kim, Y. C., Russell, R. C., Yu, F.-X., Park, H. W., Plouffe, S. W., Tagliabracci, V. S., & Guan, K.-L. (2015) · Science · doi:10.1126/science.1259472 · Cited by 757
C9orf72-mediated ALS and FTD: multiple pathways to disease
Balendra, R., & Isaacs, A. M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0047-2 · Cited by 715
Targeting RNA Foci in iPSC-Derived Motor Neurons from ALS Patients with a C9ORF72 Repeat Expansion
Sareen, D., O’Rourke, J. G., Meera, P., Muhammad, A. K. M. G., Grant, S., Simpkinson, M., Bell, S., Carmona, S., Ornelas, L., Sahabian, A., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007529 · Cited by 670 · cited 1×
“At first, while the contribution of the loss of function to the disease seemed uncertain, ASOs depleting all C9ORF72 transcripts or selectively expansion-containing transcripts were developed in parallel (Donnelly et al., 2013; Sareen et al., 2013; Lagier-Tourenne et al., 2013; Jiang et al., 2016; Gendron et al., 2017…”
BackgroundHaploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons
Shi, Y., Lin, S., Staats, K. A., Li, Y., Chang, W.-H., Hung, S.-T., Hendricks, E., Linares, G. R., Wang, Y., Son, E. Y., et al. (2018) · Nature Medicine · doi:10.1038/nm.4490 · Cited by 566 · cited 7×
“However, recent results strongly suggest that the combination of the loss-of-function effect with some gain-offunction entities is essential for the development of a pathological FTD/ALS phenotype (Shi et al., 2018; Shao et al., 2019; Lutz, 2020; Zhu et al., 2020).”
BackgroundInfluentialC9orf72 is required for proper macrophage and microglial function in mice
O’Rourke, J. G., Bogdanik, L., Yáñez, A., Lall, D., Wolf, A. J., Muhammad, A. K. M. G., Ho, R., Carmona, S., Vit, J. P., Zarrow, J., et al. (2016) · Science · doi:10.1126/science.aaf1064 · Cited by 550
Jiang, J., Zhu, Q., Gendron, T. F., Saberi, S., McAlonis-Downes, M., Seelman, A., Stauffer, J. E., Jafar-nejad, P., Drenner, K., Schulte, D., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.04.006 · Cited by 536
Farg, M. A., Sundaramoorthy, V., Sultana, J. M., Yang, S., Atkinson, R. A. K., Levina, V., Halloran, M. A., Gleeson, P. A., Blair, I. P., Soo, K. Y., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu068 · Cited by 478
Al-Sarraj, S., King, A., Troakes, C., Smith, B., Maekawa, S., Bodi, I., Rogelj, B., Al-Chalabi, A., Hortobágyi, T., & Shaw, C. E. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0911-2 · Cited by 475
Sellier, C., Campanari, M., Julie Corbier, C., Gaucherot, A., Kolb‐Cheynel, I., Oulad‐Abdelghani, M., Ruffenach, F., Page, A., Ciura, S., Kabashi, E., et al. (2016) · The EMBO Journal · doi:10.15252/embj.201593350 · Cited by 414 · cited 11×
“, 2016) and Rab39b (Sellier et al., 2016; Yang et al., 2016) and to interact with the proteins of the autophagy initiation complex FIP200/Ulk1/ATG13/ATG101 to control autophagic flux (Figure 2A; Sellier et al.”
BackgroundInfluentialThe C9orf72 protein interacts with Rab1a and the ULK1 complex to regulate initiation of autophagy
Webster, C. P., Smith, E. F., Bauer, C. S., Moller, A., Hautbergue, G. M., Ferraiuolo, L., Myszczynska, M. A., Higginbottom, A., Walsh, M. J., Whitworth, A. J., et al. (2016) · The EMBO Journal · doi:10.15252/embj.201694401 · Cited by 404
Beck, J., Poulter, M., Hensman, D., Rohrer, J. D., Mahoney, C. J., Adamson, G., Campbell, T., Uphill, J., Borg, A., Fratta, P., et al. (2013) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2013.01.011 · Cited by 345 · cited 2×
“…with age in the blood could partly explain the conflicting results reported in the literature regarding age at onset and the size of the HRE (Beck et al., 2013; Dols-Icardo et al., 2014; Hübers et al., 2014; Waite et al., 2014; Suh et al., 2015; Chen et al., 2016; Gijselinck et al., 2016;…”
BackgroundResultDipeptide repeat protein pathology in C9ORF72 mutation cases: clinico-pathological correlations
Mackenzie, I. R., Arzberger, T., Kremmer, E., Troost, D., Lorenzl, S., Mori, K., Weng, S.-M., Haass, C., Kretzschmar, H. A., Edbauer, D., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1181-y · Cited by 345 · cited 1×
“They are positive for p62 and negative for TDP-43 and may correspond to one or more dipeptides (Ash et al., 2013; Gendron et al., 2013; Mackenzie et al., 2013; Mori et al., 2013; Zu et al., 2013; Mackenzie et al., 2014).”
BackgroundCiura, S., Lattante, S., Le Ber, I., Latouche, M., Tostivint, H., Brice, A., & Kabashi, E. (2013) · Annals of Neurology · doi:10.1002/ana.23946 · Cited by 333
Self-citationLevine, T. P., Daniels, R. D., Gatta, A. T., Wong, L. H., & Hayes, M. J. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts725 · Cited by 321 · cited 1×
“Bioinformatics studies revealed that C9ORF72 shows homology to the DENN (differentially expressed in normal and neoplasia) family of proteins (Yoshimura et al., 2010; Marat et al., 2011; Levine et al., 2013).”
BackgroundC9orf72 suppresses systemic and neural inflammation induced by gut bacteria
Burberry, A., Wells, M. F., Limone, F., Couto, A., Smith, K. S., Keaney, J., Gillet, G., van Gastel, N., Wang, J.-Y., Pietilainen, O., et al. (2020) · Nature · doi:10.1038/s41586-020-2288-7 · Cited by 314
Moore, K. M., Nicholas, J., Grossman, M., McMillan, C. T., Irwin, D. J., Massimo, L., Van Deerlin, V. M., Warren, J. D., Fox, N. C., Rossor, M. N., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30394-1 · Cited by 313
mTORC2 controls actin polymerization required for consolidation of long-term memory
Huang, W., Zhu, P. J., Zhang, S., Zhou, H., Stoica, L., Galiano, M., Krnjević, K., Roman, G., & Costa-Mattioli, M. (2013) · Nature Neuroscience · doi:10.1038/nn.3351 · Cited by 307
C9orf72 in myeloid cells suppresses STING-induced inflammation
McCauley, M. E., O’Rourke, J. G., Yáñez, A., Markman, J. L., Ho, R., Wang, X., Chen, S., Lall, D., Jin, M., Muhammad, A. K. M. G., et al. (2020) · Nature · doi:10.1038/s41586-020-2625-x · Cited by 298
Sullivan, P. M., Zhou, X., Robins, A. M., Paushter, D. H., Kim, D., Smolka, M. B., & Hu, F. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0324-5 · Cited by 295
Loss-of-function mutations in the C9ORF72 mouse ortholog cause fatal autoimmune disease
Burberry, A., Suzuki, N., Wang, J.-Y., Moccia, R., Mordes, D. A., Stewart, M. H., Suzuki-Uematsu, S., Ghosh, S., Singh, A., Merkle, F. T., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6038 · Cited by 269 · cited 5×
“…all C9orf72 knockout mouse models strikingly develop immune abnormalities and autoimmune-like diseases (Koppers et al., 2015; Atanasio et al., 2016; Burberry et al., 2016; Jiang et al., 2016; O’Rourke et al., 2016; Sudria-Lopez et al., 2016; Sullivan et al., 2016; Ugolino et al., 2016).”
BackgroundInfluentialGendron, T. F., Chew, J., Stankowski, J. N., Hayes, L. R., Zhang, Y.-J., Prudencio, M., Carlomagno, Y., Daughrity, L. M., Jansen-West, K., Perkerson, E. A., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aai7866 · Cited by 265
Atanasio, A., Decman, V., White, D., Ramos, M., Ikiz, B., Lee, H.-C., Siao, C.-J., Brydges, S., LaRosa, E., Bai, Y., et al. (2016) · Scientific Reports · doi:10.1038/srep23204 · Cited by 263 · cited 8×
“…exons 2–6 of the endogenous C9orf72 gene, the activity of the C9orf72 promoter is found in several tissues (lung, heart, liver, spleen, and kidney muscle), with the highest levels in the brain and spinal cord (Suzuki et al., 2013; Atanasio et al., 2016; Jiang et al., 2016; Langseth et al., 2017).”
BackgroundInfluentialZhang, D., Iyer, L. M., He, F., & Aravind, L. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2012.00283 · Cited by 244
on behalf of the BELNEU CONSORTIUM, Gijselinck, I., Van Mossevelde, S., van der Zee, J., Sieben, A., Engelborghs, S., De Bleecker, J., Ivanoiu, A., Deryck, O., Edbauer, D., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.159 · Cited by 242 · cited 1×
“STING signaling is regulated by the autophagolysosomal pathway, and blocking its degradation leads to sustained IFN-I production (Konno et al., 2013; Gonugunta et al., 2017; Prabakaran et al., 2018).”
BackgroundA C9ORF72/SMCR8-containing complex regulates ULK1 and plays a dual role in autophagy
Yang, M., Liang, C., Swaminathan, K., Herrlinger, S., Lai, F., Shiekhattar, R., & Chen, J.-F. (2016) · Science Advances · doi:10.1126/sciadv.1601167 · Cited by 238 · cited 3×
“…forms a tripartite trimer with other DENN domain-containing proteins, SMCR8 (Smith–Magenis chromosome region 8) and WDR41 (WD40-repeat containing protein 41) (Figure 2D; Amick et al., 2016; Blokhuis et al., 2016; Sellier et al., 2016; Sullivan et al., 2016; Ugolino et al., 2016; Yang et al., 2016).”
BackgroundMackenzie, I. R. A., Frick, P., Grässer, F. A., Gendron, T. F., Petrucelli, L., Cashman, N. R., Edbauer, D., Kremmer, E., Prudlo, J., Troost, D., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1476-2 · Cited by 231
Zhu, Q., Jiang, J., Gendron, T. F., McAlonis-Downes, M., Jiang, L., Taylor, A., Diaz Garcia, S., Ghosh Dastidar, S., Rodriguez, M. J., King, P., et al. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0619-5 · Cited by 220
The neuropathology associated with repeat expansions in the C9ORF72 gene
Mackenzie, I. R. A., Frick, P., & Neumann, M. (2014) · Acta Neuropathologica · doi:10.1007/s00401-013-1232-4 · Cited by 206 · cited 3×
“Pathologically, C9ORF72 expansion carriers present TDP43 inclusions in neurons and oligodendroglial cells that do not overlap with the neuronal DPRs and RNA foci in neurons and glial cells (Mizielinska et al., 2013; Mackenzie et al., 2014).”
BackgroundLoss of C9orf72 Enhances Autophagic Activity via Deregulated mTOR and TFEB Signaling
Ugolino, J., Ji, Y. J., Conchina, K., Chu, J., Nirujogi, R. S., Pandey, A., Brady, N. R., Hamacher-Brady, A., & Wang, J. (2016) · PLOS Genetics · doi:10.1371/journal.pgen.1006443 · Cited by 185 · cited 4×
“…phenotype, sometimes associated with a shortened life span, but no neurodegeneration or motor neuron disease (Koppers et al., 2015; Atanasio et al., 2016; Burberry et al., 2016; Jiang et al., 2016; O’Rourke et al., 2016; SudriaLopez et al., 2016; Sullivan et al., 2016; Ugolino et al., 2016).”
BackgroundInfluentialAutoimmune disease preceding amyotrophic lateral sclerosis: An epidemiologic study
Turner, M. R., Goldacre, R., Ramagopalan, S., Talbot, K., & Goldacre, M. J. (2013) · Neurology · doi:10.1212/wnl.0b013e3182a6cc13 · Cited by 185
Deletion of C9ORF72 Results in Motor Neuron Degeneration and Stress Sensitivity in C. elegans
Therrien, M., Rouleau, G. A., Dion, P. A., & Parker, J. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083450 · Cited by 183 · cited 1×
“In zebrafish and Caenorhabditis elegans, C9ORF72 loss of function resulted in locomotor phenotypes and motoneuron degeneration (Ciura et al., 2013; Therrien et al., 2013).”
BackgroundC9orf72 hypermethylation protects against repeat expansion-associated pathology in ALS/FTD
Liu, E. Y., Russ, J., Wu, K., Neal, D., Suh, E., McNally, A. G., Irwin, D. J., Van Deerlin, V. M., & Lee, E. B. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1286-y · Cited by 180
TDP-43 frontotemporal lobar degeneration and autoimmune disease
Miller, Z. A., Rankin, K. P., Graff-Radford, N. R., Takada, L. T., Sturm, V. E., Cleveland, C. M., Criswell, L. A., Jaeger, P. A., Stan, T., Heggeli, K. A., et al. (2013) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-304644 · Cited by 170
Laflamme, C., McKeever, P. M., Kumar, R., Schwartz, J., Kolahdouzan, M., Chen, C. X., You, Z., Benaliouad, F., Gileadi, O., McBride, H. M., et al. (2019) · eLife · doi:10.7554/elife.48363 · Cited by 155
Sudria-Lopez, E., Koppers, M., de Wit, M., van der Meer, C., Westeneng, H.-J., Zundel, C. A. C., Youssef, S. A., Harkema, L., de Bruin, A., Veldink, J. H., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1581-x · Cited by 130
Increased prevalence of autoimmune disease within C9 and FTD/MND cohorts: Completing the picture
Miller, Z. A., Sturm, V. E., Camsari, G. B., Karydas, A., Yokoyama, J. S., Grinberg, L. T., Boxer, A. L., Rosen, H. J., Rankin, K. P., Gorno-Tempini, M. L., et al. (2016) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000301 · Cited by 100
Synaptic dysfunction and altered excitability in C9ORF72 ALS/FTD
Starr, A., & Sattler, R. (2018) · Brain Research · doi:10.1016/j.brainres.2018.02.011 · Cited by 78 · cited 1×
“Although little is known about the excitotoxicity mechanisms in FTD, in ALS, it is one of the major contributing mechanisms involved in the degeneration of motor neurons, and there is evidence that it is involved in C9-FTD/ALS (Starr and Sattler, 2018).”
BackgroundChai, N., Haney, M. S., Couthouis, J., Morgens, D. W., Benjamin, A., Wu, K., Ousey, J., Fang, S., Finer, S., Bassik, M. C., et al. (2020) · Brain Research · doi:10.1016/j.brainres.2019.146601 · Cited by 26
Cited by
Advances in molecular pathology, diagnosis, and treatment of amyotrophic lateral sclerosis
Ilieva, H., Vullaganti, M., & Kwan, J. (2023) · BMJ · doi:10.1136/bmj-2023-075037 · Cited by 111
Current Concepts on Genetic Aspects of Mitochondrial Dysfunction in Amyotrophic Lateral Sclerosis
Jankovic, M., Novakovic, I., Gamil Anwar Dawod, P., Gamil Anwar Dawod, A., Drinic, A., Abdel Motaleb, F. I., Ducic, S., & Nikolic, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189832 · Cited by 36
Metadata
- Authors
- Smeyers, J., Banchi, E.-G., & Latouche, M.
- Venue
- Frontiers in Cellular Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2021-05-05
- Volume
- 15
- Pages
- 661447-661447
- ISSN
- 1662-5102 (ISSN-L)
- OpenAlex
- W3157095124
- Cited by
- 168
- References
- 48
- FWCI
- 10.72
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.